Specialty Pharma Dominates Epilepsy Market, But Does It Have Resources To Develop Disease-Modifying Agents?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Upsher-Smith’s recent acquisition of research boutique Proximagen highlights the dynamics of the market: specialty pharma extending dominance and introducing new agents to the market, while most early R&D activity originates at small firms. But it may be difficult for this combination of players to bring forth the game-changing therapies that are needed, given the technical challenges of the disease space.